ELLIVASE Trademark

Trademark Overview


On Tuesday, June 13, 2023, a trademark application was filed for ELLIVASE with the United States Patent and Trademark Office. The USPTO has given the ELLIVASE trademark a serial number of 98040733. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, July 31, 2024. This trademark is owned by Vanda Pharmaceuticals Inc.. The ELLIVASE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatm...
ellivase

General Information


Serial Number98040733
Word MarkELLIVASE
Filing DateTuesday, June 13, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, July 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 18, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameVanda Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Party NameVanda Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Trademark Events


Event DateEvent Description
Friday, June 16, 2023NEW APPLICATION ENTERED
Monday, November 13, 2023ASSIGNED TO EXAMINER
Thursday, November 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, July 31, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 31, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 1, 2024SOU EXTENSION 1 GRANTED
Thursday, August 1, 2024SOU EXTENSION 1 FILED
Tuesday, February 13, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT